(NASDAQ: BBIO) Bridgebio Pharma's forecast annual revenue growth rate of 107.44% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.57%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.38%.
Bridgebio Pharma's revenue in 2025 is $127,415,000.On average, 6 Wall Street analysts forecast BBIO's revenue for 2025 to be $93,888,420,811, with the lowest BBIO revenue forecast at $65,525,937,665, and the highest BBIO revenue forecast at $143,384,628,094. On average, 6 Wall Street analysts forecast BBIO's revenue for 2026 to be $129,233,957,316, with the lowest BBIO revenue forecast at $94,921,371,928, and the highest BBIO revenue forecast at $171,595,206,664.
In 2027, BBIO is forecast to generate $228,290,931,326 in revenue, with the lowest revenue forecast at $169,924,256,328 and the highest revenue forecast at $289,226,312,704.